Health
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses – Business Wire
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations. The company presented the results in an oral presentation at the 28th Conference on Retroviruses and Opportunistic Infections (CROI) and published the positive findings of high binding affinity to the variants in preprint server, bioRxiv…
-
Noosa News24 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
Noosa News21 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General20 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity
-
General17 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank